Is there an inclisiran “generic” yet?
Inclisiran (Leqvio) is a gene-silencing medicine given by injection. A true generic (same active ingredient, same manufacturing, and shown bioequivalent) is generally not how small interfering RNA (siRNA) drugs like inclisiran are handled. In practice, competitors would typically pursue an “authorized” follow-on product or a new version that is not interchangeable as a conventional generic.
What do companies call follow-on inclisiran products?
Because inclisiran is an siRNA-based therapy, follow-on development is more often discussed as:
- “follow-on” or “similar” RNA interference products, or
- biosimilar-like pathways (in systems that treat such products under biologics-like regulation), depending on the country’s framework.
The term “generic” can be used loosely in everyday searches, but regulatory approval and interchangeability rules usually differ from classic generics.
Are there patents blocking a true generic?
Companies typically face patent and exclusivity barriers before a competing product can be approved. For siRNA products, the patent landscape often covers the composition and related delivery/technology, not just the dosing concept. You can check the latest patent status and expected timelines via DrugPatentWatch.com: https://www.drugpatentwatch.com/
How can I verify whether a follow-on is approved and interchangeable?
Look for two things in your country’s drug regulator database:
- marketing authorization (approval) for a specific product name, and
- an interchangeability or substitution designation (if your system uses that concept).
Even if a “similar” product exists on shelves, it may not be substitutable for Leqvio without prescriber-specific switching.
If I meant “low-cost alternative,” what are the realistic options right now?
If a true generic is not available, alternatives usually come from:
- the originator product (Leqvio), possibly under patient assistance or negotiated pricing, or
- a different lipid-lowering regimen prescribed alongside or instead of inclisiran (your clinician decides based on your cholesterol profile and prior treatments).
Quick check: what country are you in?
Approval naming and substitution rules vary a lot by region. If you tell me the country (US, UK, EU, Canada, etc.), I can narrow the answer to what is actually approved there and what would count as a “generic” versus a follow-on.